Diagnostics and Antivirals for Emerging Viruses
A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Virology".
Deadline for manuscript submissions: closed (10 December 2023) | Viewed by 990
Special Issue Editors
Interests: nanotechnology; immunotherapy; brain tumor
Special Issues, Collections and Topics in MDPI journals
Interests: biomarkers; resistance; imaging; nanotechnology; long-acting therapeutics; diagnosis; liposomes; lipid nanoparticles
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Emerging viruses such as filoviruses (Ebola; Marburg), SARS and MERS coronaviruses and zika post major threats to people living with co-morbidities worldwide. Therefore, developing accurate and highly sensitive diagnostics in parallel to safe and effective therapeutic modalities against emerging viruses is essential. Long-acting prodrugs and nanoparticles, immunotherapeutic modalities such monoclonal antibodies and fusion proteins, peptides and CRISPR Cas9 systems are some of the emerging modalities for viral restriction and eventual elimination, which need to be moved forward to clinical studies individually and in combination for their enhanced therapeutic benefits in patients.
These goals will only be achieved by joining efforts from multiple disciplines including virology, geneticists, formulation scientists, clinicians, immunologists, medicinal chemists, etc.
The aim of this Special Issue is to provide an adequate multidisciplinary platform for the interchange of valuable information (both basic and applied research) that aids in the development of diagnostics, mRNA vaccines, RNA/CRISPR modalities and long-acting nanotherapeutics against emerging viruses directed towards efficient and safe treatments against these emerging viruses.
As a Guest Editor of the Special Issue, I invite you to submit research articles, review articles, and short communications related to diagnostics, therapeutic gene and vaccine delivery, lipid and polymeric nanoparticulate systems and loading biologics/small molecule inhibitors targeted towards the restriction and elimination of emerging viruses.
Dr. Héctor R. Méndez-Gómez
Dr. Dhruvkumar M. Soni
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanotechnology
- gene therapy
- vaccines
- cancer
- biomarkers
- long-acting therapeutics
- CRISPR Cas9
- infectious diseases
